S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

VBI Vaccines (NASDAQ:VBIV) Upgraded at Zacks Investment Research

Saturday, May 14, 2022 | MarketBeat

VBI Vaccines (NASDAQ:VBIV - Get Rating) was upgraded by Zacks Investment Research from a "sell" rating to a "hold" rating in a note issued to investors on Friday, Zacks.com reports.

According to Zacks, "VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. "

Separately, Raymond James dropped their price objective on shares of VBI Vaccines from $9.00 to $6.00 and set a "strong-buy" rating for the company in a report on Tuesday, March 8th.

Shares of NASDAQ:VBIV traded down $0.01 during trading on Friday, hitting $1.06. 17,655 shares of the company were exchanged, compared to its average volume of 1,827,229. VBI Vaccines has a 1-year low of $0.96 and a 1-year high of $4.31. The company has a market capitalization of $273.76 million, a P/E ratio of -3.82 and a beta of 2.01. The company has a quick ratio of 3.92, a current ratio of 3.31 and a debt-to-equity ratio of 0.19. The business's 50 day moving average is $1.48 and its 200-day moving average is $1.98.

VBI Vaccines (NASDAQ:VBIV - Get Rating) last issued its quarterly earnings data on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). VBI Vaccines had a negative return on equity of 48.77% and a negative net margin of 16,087.72%. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.14 million. As a group, sell-side analysts anticipate that VBI Vaccines will post -0.28 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of VBI Vaccines by 3.6% in the fourth quarter. BlackRock Inc. now owns 13,269,221 shares of the biopharmaceutical company's stock worth $31,049,000 after acquiring an additional 462,785 shares during the period. State Street Corp increased its position in shares of VBI Vaccines by 1.4% during the fourth quarter. State Street Corp now owns 12,372,113 shares of the biopharmaceutical company's stock valued at $28,951,000 after acquiring an additional 176,533 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of VBI Vaccines by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,896,078 shares of the biopharmaceutical company's stock worth $12,116,000 after purchasing an additional 238,896 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of VBI Vaccines by 2.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 2,189,700 shares of the biopharmaceutical company's stock worth $3,635,000 after buying an additional 43,192 shares during the last quarter. Finally, Northern Trust Corp grew its position in VBI Vaccines by 3.6% during the fourth quarter. Northern Trust Corp now owns 1,988,351 shares of the biopharmaceutical company's stock valued at $4,653,000 after buying an additional 68,218 shares during the period. 43.24% of the stock is owned by institutional investors.

About VBI Vaccines (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

See Also

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in VBI Vaccines right now?

Before you consider VBI Vaccines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VBI Vaccines wasn't on the list.

While VBI Vaccines currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.